HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc 1 complex

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3739-3747

  Vallières, Cindy ^a   Fisher, Nicholas ^b,d   Antoine, Thomas ^b   Al Helal, Mohammed ^b   Stocks, Paul ^b   Berry, Neil G ^c   Lawrenson, Alexandre S ^c   Ward, Stephen A ^b   O'Neill, Paul M ^c   Biagini, Giancarlo A ^b   Meunier, Brigitte ^a  

^a CNRS   (France)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXY 2 DODECYL 4(1H) QUINOLONE; 4 QUINOLONE DERIVATIVE; ATOVAQUONE; QUINONE DERIVATIVE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BINDING; ENZYME ACTIVITY; NONHUMAN; PLASMODIUM FALCIPARUM; POINT MUTATION; PRIORITY JOURNAL; REDUCTION;

ANTIMALARIALS; BINDING SITES; ELECTRON TRANSPORT COMPLEX III; PLASMODIUM FALCIPARUM; QUINOLONES;

EID: 84862517565     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00486-12     Document Type: Article

References (49)

1. Barton V, Fisher N, Biagini GA, Ward SA, O'Neill P. 2010. Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr. Opin. Chem. Biol.14:1-7.
2. Berry A, et al. 2006. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans. R. Soc. Trop. Med. Hyg. 100:986-988. (Pubitemid 44164199)
3. Berry EA, et al. 2010. Ascochlorin is a novel, specific inhibitor of the mitochondrial cytochrome bc1 complex. Biochim. Biophys. Acta 1797:360-370.
4. Biagini G, et al. 2008. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol. Pharmacol. 73:1347-1355. (Pubitemid 351574824)
5. Biagini GA, Viriyavejakul P, O'Neill PM, Bray PG, Ward SA. 2006. Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob. Agents Chemother. 50:1841-1851.
6. Boulton IC, et al. 2010. CRIMALDDI: a coordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives. Malar. J. 9:202.
7. Boysen KE, Matuschewski K. 2011. Arrested oocyst maturation in Plasmodium parasites lacking type II NADH:ubiquinone dehydrogenase. J. Biol. Chem. 286:32661-32671.
8. Brasseur G, Brivet-Chevillotte P. 1995. Characterization of mutations in the mitochondrial cytochrome b gene of Saccharomyces cerevisiae affecting the quinone reductase site (Qn). Eur. J. Biochem. 230:1118-1124.
9. Brasseur G, Coppee J-Y, Colson A-M, Brivet-Chevillotte P. 1995. Structure-function relationships of the mitochondrial bc1 complex in temper-ature- sensitive mutants of the cytochrome b gene, impaired in the catalytic center N. J. Biol. Chem. 270:29356-29364.
10. Brasseur G, Saribas AS, Daldal F. 1996. A compilation of mutations located in the cytochrome b subunit of the bacterial and mitochondrial bc1 complex. Biochim. Biophys. Acta 1275:61- 69.
11. Coppee J-Y, Brasseur G, Brivet-Chevillotte P, Colson A-M. 1994. Nonnative intragenic reversions selected from Saccharomyces cerevisiae cytochrome b-deficient mutants. J. Biol. Chem. 269:4221-4226.
12. Crofts AR, et al. 1999. Mechanism of ubiquinol oxidation by the bc1 complex: different domains of the quinol binding pocket and their role in the mechanism and binding of inhibitors. Biochemistry 38:15807-15826. (Pubitemid 129520473)
13. Ding MG, di Rago J-P, Trumpower BL. 2006. Investigating the Qn site of the cytochrome bc1 complex in Saccharomyces cerevisiae with mutants resistant to ilicicolin H, a novel Qn site inhibitor. J. Biol. Chem. 281:36036-36043. (Pubitemid 46043243)
14. di Rago J-P, Colson A-M. 1988. Molecular basis for resistance to antimycin and diruon, Q-cycle inhibitors acting at the Qi site in the mitochondrial ubiquinol-cytochrome c reductase in Saccharomyces cerevisiae. J. Biol. Chem. 263:12564 -12570.
15. Dong CK, et al. 2009. Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors. Bioorg. Med. Chem. Lett. 19:972-975.
16. Eschemann A, Galkin AG, Oettmeier W, Brandt U, Kerscher S. 2005. HDQ (1-hydroxy-2-dodecyl-4(1H)quinolone), a high-affinity inhibitor for mitochondrial alternative NADH dehydrogenase. J. Biol. Chem. 280:3138-3142. (Pubitemid 40223774)
17. Esser L, et al. 2004. Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for cytochrome bc1 complex. J. Mol. Biol. 341:281-302. (Pubitemid 39090651)
18. Fisher N, Bray PG, Ward SA, Biagini GA. 2007. The malaria parasite type II NADH:quinone oxidoreductase: and alternative enzyme for an alternative lifestyle. Trends Parasitol. 23:305-310. (Pubitemid 46935569)
19. Fisher N, et al. 2004. Human disease-related mutations in cytochrome b studied in yeast. J. Biol. Chem. 279:12951-12958. (Pubitemid 38445870)
20. Fisher N, Meunier B. 2005. Re-examination of inhibitor resistance conferred by Qo site mutations in cytochrome b using yeast as a model system. Pest. Manag. Sci. 61:973-978. (Pubitemid 41367962)
21. Fisher N, Meunier B. 2008. Molecular basis of resistance to cytochrome bc1 inhibitors. FEMS Yeast Res. 8:183-192. (Pubitemid 351208182)
22. Fisher N, Warman AJ, Ward SA, Biagini GA. 2009. Chapter 17 type II NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays. Methods Enzymol. 456:303-320.
23. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G. 2002. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar. J. 1:1.
24. Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy- 1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43:1545-1553.
25. Gao X, et al. 2003. Structural basis for the quinone reduction in the bc1 complex: a comparative analysis of crystal structures of mitochondrial cytochrome bc1 with bound substrate and inhibitors at the Qi site. Biochemistry 42:9067-9080. (Pubitemid 36935415)
26. Hill P, et al. 2003. Recapitulation in Saccharomyces cerevisiae of cytochrome b mutations conferring resistance to atovaquone in Pneumocystis jiroveci. Antimicrob. Agents Chemother. 47:2725-2731. (Pubitemid 37040240)
27. Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682- 690.
28. Huang L-S, Cobessi D, Tung E, Berry EA. 2005. Binding of the respiratory chain inhibitor antimycin to the mitochondrial bc1 complex: a new crystal structure reveals an altered intramolecular hydrogen-bonding pattern. J. Mol. Biol. 351:573-597. (Pubitemid 41021942)
29. Hunte C, Koepke J, Lange C, Rossmanith T, Michel H. 2000. Structure at 2.3 angstrom resolution of the cytochrome bc1 complex from the yeast Saccharomyces cerevisiae co-crystallized with an antibody Fv fragment. Struct. Fold. Des. 8:669-684. (Pubitemid 30409318)
30. Hunte C, Palsdottir H, Trumpower BL. 2003. Protonmotive pathways and mechanisms in the cytochrome bc1 complex. FEBS Lett. 545:39-46. (Pubitemid 36629634)
31. Kessl J, et al. 2005. Cytochrome b mutations that modify the ubiquinol-binding pocket if the cytochrome bc1 and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J. Biol. Chem. 280:17142-17148. (Pubitemid 41389179)
32. Lambros C, Vanderberg JP. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420. (Pubitemid 10222999)
33. Lemaire C, Dujardin G. 2008. Preparation of respiratory chain complexes from Saccharomyces cerevisiae wild-type and mutant mitochondria: activity measurement and subunit composition analysis. Methods Mol. Biol. 432:65-81.
34. Lin SS, Gross U, Bohne W. 2009. Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii. Eukaryot. Cell 8:877-887.
35. Lin SS, Gross U, Bohne W. 2011. Two internal type II NADH dehydrogenases of Toxoplasma gondii are both required for optimal tachyzoite growth. Mol. Microbiol. 82:209-221.
36. Lin SS, et al. 2008. The Toxoplasma gondii type-II NADH dehydrogenase TgNDH2-I is inhibited by 1-hydroxy-2-alkyl-4(1H)quinolones. Biochim. Biophys. Acta 1777:1455-1462.
37. Mitani S, et al. 2001. The biochemical mode of action of the novel selective fungicide Cyazofamid: specific inhibition of mitochondrial complex III in Phythium spinosum. Pestic. Biochem. Physiol. 71:107-115. (Pubitemid 33017120)
38. Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J. 2006. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 8:2599-2604. (Pubitemid 44604457)
39. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. 2007. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446:88-91. (Pubitemid 46348043)
40. Saleh A, Friesen J, Baumeister S, Gross U, Bohne W. 2007. Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H) quinolone, a highaffinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob. Agents Chemother. 51:1217-1222. (Pubitemid 46586796)
41. Schwartz E, Bujanover S, Kain KC. 2003. Genetic confirmation of atova-quone- proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin. Infect. Dis. 37:450-451. (Pubitemid 36976505)
42. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806. (Pubitemid 38544392)
43. Solmaz SR, Hunte C. 2008. Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer. J. Biol. Chem. 283:17542-17549.
44. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB. 1999. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33:704 -711.
45. Srivastava IK, Rottenburg Vaidya AB. 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem. 272:3961-3966. (Pubitemid 27078454)
46. Tietze LF, Ma L. 2010. Synthesis of novel 1-hydroxyquinolones with high anti-toxoplasma activity. Heterocycles 82:377-396.
47. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
48. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. 2003. Improved protein-ligand docking using GOLD. Proteins 52:609-623. (Pubitemid 37034158)
49. Woschek A, Mahout M, Mereiter K, Hammerschmidt F. 2007. Synthesis of 2-heptyl-1-hydroxy-4(1H)-quinolone: unexpected rearrangement of 4-(alkoxycarbonyloxy)quinoline N-oxides to 1-(alkoxycarbonyl-oxy)-4(1H)- quinolones. Synthesis Stuttgart 10:1517-1522. (Pubitemid 46847962)